Ministers agreed last week to a two-week extension to the deadline by which pharma firms must tell the government if they intend to leave the NHS’s voluntary drug pricing scheme, signaling that a breakthrough in talks is imminent.
Greer’s visit comes just two days before Chancellor Rachel Reeves’ budget, and British officials are eager to finalize the pharma deal ahead of that announcement, said two of the people cited higher. They were granted anonymity to speak freely on a sensitive matter.
If Washington accepts the proposal — effectively committing the NHS to higher drug spending — Reeves will face pressure to spell out how much the increase will cost taxpayers.
A Department of Health and Social Care spokesperson said: “We will always prioritise the needs of NHS patients. Investment in patient access to innovative medicines is critical to our NHS.”
“We are now in advanced discussions with the US Administration to secure the best outcome for the UK, reflecting our strong relationship and the opportunities from close partnership with our pharmaceutical industry,” the spokesperson added.
Trump’s asks
Washington, meanwhile, is pushing for more.
